The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2022 | Unanswered questions regarding the use of IO in NSCLC
Jarushka Naidoo, MD, John Hopkins University, Baltimore, MD, talks on unanswered questions regarding the use of immune checkpoint inhibitors (ICIs) in non-small cell lung cancer (NSCLC), including the uncertain role of immunotherapy (IO) in the early stages of NSCLC and whether there are biomarkers beyond PD-L1 for selecting patients for IO, as well as biomarkers for predicting toxicity. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.
